论文部分内容阅读
据Burrill公司最近的报告,1998年美国医药生物技术产业的销售达到历年来的顶峰,达201亿美元;增长了14.9％。当然,这些成绩的取得仍然依赖于一些大公司。20个主要的生物技术企业,其市值占了生物技术产业总市值1489亿美元的2/3,比1997年同期增长了37％。而其它1000家以上的上市公司,其市值只有2500万美元,上市公司的亏损已经从1997年的27亿美元减少到1998年的19亿美元。说明生物技术产业已逐步趋于成熟。 但是,在生物技术产业方面仍然存在一些不足的地方,如金融市场的开发程度不够,资金的筹措仍然有相当的难
According to a recent report by Burrill, in 1998, sales of the pharmaceutical biotechnology industry in the United States reached the peak of the year, reaching US$20.1 billion, an increase of 14.9%. Of course, these achievements still rely on some big companies. The 20 major biotech companies have a market value of 2/3 of the total market value of the biotechnology industry of US$148.9 billion, an increase of 37% over the same period in 1997. The other 1,000 or more listed companies have a market value of only 25 million U.S. dollars. The losses of listed companies have decreased from 2.7 billion U.S. dollars in 1997 to 1.9 billion U.S. dollars in 1998. It shows that the biotechnology industry has gradually matured. However, there are still some deficiencies in the biotechnology industry, such as insufficient development of financial markets, and the financing of funds is still quite difficult.